Prognostic impact of HER-2/neu expression on squamous head and neck carcinomas

被引:61
作者
Cavalot, Andrea
Martone, Tiziana
Roggero, Nicolo
Brondino, Gabriele
Pagano, Marco
Cortesina, Giorgio [1 ]
机构
[1] Univ Turin, Div Otorhinolaryngol, Dept Clin Physiopathol, Turin, Italy
[2] Univ Turin, Informat Unit, Dept Clin Physiopathol, Turin, Italy
[3] Univ Turin, Div Pathol, Dept Biomed Sci & Oncol, Turin, Italy
来源
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK | 2007年 / 29卷 / 07期
关键词
head and neck squamous cell carcinoma (HNSCC); HER-2/neu; immunohistochemistry; TNM stage; prognosis;
D O I
10.1002/hed.20574
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Background. HER-2/neu gene amplification and protein overexpression have been identified in various solid tumors, but its prognostic relevance in head and neck squamous cell carcinoma (HNSCC) is still controversial. Methods, The study investigated the expression of HER-2/ neu oncoprotein in HNSCC and sought possible correlations to various clinicopathologic parameters. Expression of HER-2/neu oncoprotein was assessed in archival tumor tissues from 87 untreated HNSCC patients by immunohistochemical technique. Data were correlated with both the clinicopathologic parameters and patient survival. Results. A high membranous HER-2/neu protein expression level was found in 39% of patients. Multivariate analysis indicated that HER-2/neu protein expression and pN lymph-node status were independent prognostic factors for disease-free survival. Conclusions. HER2/neu overexpression and its relationship with survival suggest that new therapeutic approaches targeting epidermal growth factor receptor (EGFR) family receptors could provide a new way of treating HNSCC patients with HER2/neupositive neoplastic lesions, (c) 2007 Wiley Periodicals, Inc.
引用
收藏
页码:655 / 664
页数:10
相关论文
共 61 条
[1]  
BECHHARDT RN, 1995, ARCH OTOLARYNGOL, V121, P1265
[2]  
BOYLE JO, 1993, CANCER RES, V53, P4477
[3]  
Ciardiello F, 2001, CLIN CANCER RES, V7, P2958
[4]   NCL-CB11, A NEW MONOCLONAL-ANTIBODY RECOGNIZING THE INTERNAL DOMAIN OF THE C-ERBB-2 ONCOGENE PROTEIN EFFECTIVE FOR USE ON FORMALIN-FIXED, PARAFFIN-EMBEDDED TISSUE [J].
CORBETT, IP ;
HENRY, JA ;
ANGUS, B ;
WATCHORN, CJ ;
WILKINSON, L ;
HENNESSY, C ;
GULLICK, WJ ;
TUZI, NL ;
MAY, FEB ;
WESTLEY, BR ;
HORNE, CHW .
JOURNAL OF PATHOLOGY, 1990, 161 (01) :15-25
[5]  
CRAVEN JM, 1992, ANTICANCER RES, V12, P2273
[6]   Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients [J].
Crombet, T ;
Osorio, M ;
Cruz, T ;
Roca, C ;
del Castillo, R ;
Mon, R ;
Iznaga-Escobar, N ;
Figueredo, R ;
Koropatnick, J ;
Renginfo, E ;
Fernández, E ;
Alvárez, D ;
Torres, O ;
Ramos, M ;
Leonard, I ;
Pérez, R ;
Lage, A .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (09) :1646-1654
[7]   EXPRESSION OF EPIDERMAL GROWTH-FACTOR RECEPTOR AND SURVIVAL IN UPPER AERODIGESTIVE TRACT CANCER [J].
DASSONVILLE, O ;
FORMENTO, JL ;
FRANCOUAL, M ;
RAMAIOLI, A ;
SANTINI, J ;
SCHNEIDER, M ;
DEMARD, F ;
MILANO, G .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (10) :1873-1878
[8]  
de Jong RJB, 2001, HEAD NECK-J SCI SPEC, V23, P718
[9]  
DEMILIA J, 1989, ONCOGENE, V4, P1233
[10]  
Eccles SA, 2000, RECENT RESULTS CANC, V157, P41